1. Home
  2. BIRD vs SCLX Comparison

BIRD vs SCLX Comparison

Compare BIRD & SCLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Allbirds Inc.

BIRD

Allbirds Inc.

HOLD

Current Price

$2.39

Market Cap

30.1M

ML Signal

HOLD

Logo Scilex Holding Company

SCLX

Scilex Holding Company

HOLD

Current Price

$5.17

Market Cap

35.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BIRD
SCLX
Founded
2015
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Apparel
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
30.1M
35.2M
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
BIRD
SCLX
Price
$2.39
$5.17
Analyst Decision
Hold
Analyst Count
1
0
Target Price
$8.00
N/A
AVG Volume (30 Days)
604.5K
32.7K
Earning Date
05-07-2026
04-10-2026
Dividend Yield
N/A
N/A
EPS Growth
20.22
N/A
EPS
N/A
N/A
Revenue
$152,466,000.00
$30,253,000.00
Revenue This Year
N/A
$122.52
Revenue Next Year
$35.12
$186.30
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.15
$4.20
52 Week High
$24.31
$30.90

Technical Indicators

Market Signals
Indicator
BIRD
SCLX
Relative Strength Index (RSI) 45.67 42.04
Support Level $2.22 $4.20
Resistance Level $2.71 $7.77
Average True Range (ATR) 0.12 0.29
MACD 0.01 0.06
Stochastic Oscillator 46.97 48.28

Price Performance

Historical Comparison
BIRD
SCLX

About BIRD Allbirds Inc.

Smartbird Inc delivers dedicated AI infrastructure as a service, giving organizations the performance, control, and security of a private AI cluster without requiring them to finance, operate, or maintain the underlying infrastructure. Smartbird manages the entire lifecycle, from procurement and deployment to operations and hardware refreshes, so customers can focus on AI workloads, not AI infrastructure.

About SCLX Scilex Holding Company

Scilex Holding Co is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. It targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Its commercial products are: ZTlidoO for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a potential first-line treatment ready-to-use oral solution for the acute treatment of migraine in adults and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.

Share on Social Networks: